Delving into the Latest Updates on Jiangsu Jingze Biomedical Co Ltd with Synapse

Overview

Basic Info

Introduction

Established in 2014, Jingze Biomedical (Hefei) Co Ltd. concentrates on the specialized sectors of assisted reproductive technology and ophthalmology. The company's mission is dedicated to innovating and industrializing novel pharmaceuticals by leveraging cutting-edge biotechnologies. The headquarters are located in Hefei.

Tags

Eye Diseases

Endocrinology and Metabolic Disease

Urogenital Diseases

Biological products

Biosimilar

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	7
Nervous System Diseases	2

Top 5 Drug Type	Count

Biological products	7
Biosimilar	6
Monoclonal antibody	4
Fusion protein	2
Hormone	2

Top 5 Target	Count

FSHR(Follicle-stimulating hormone receptor)	3
PGF x VEGF-A	1
miR-22(microRNA 22)	1
PLG(Plasminogen)	1

以默克雪兰诺公司生产的重组人促卵泡激素注射液(果纳芬®)为参比制剂，以成都景泽生物制药有限公司提供的重组人促卵泡激素注射液(代号：JZB33)为受试制剂，通过单中心、随机、开放、双周期、交叉、单次皮下注射给药设计的生物等效性试验，评估两种制剂在中国健康成年女性受试者中应用的安全性、药代动力学行为及免疫原性，为产品上市提供参考依据。

[Translation]

Using recombinant human follicle-stimulating hormone injection (GONA-f®) produced by Merck Serono as the reference preparation and recombinant human follicle-stimulating hormone injection (code: JZB33) provided by Chengdu Jingze Biopharmaceutical Co., Ltd. as the test preparation, a single-center, randomized, open, two-period, crossover, single subcutaneous injection bioequivalence study was conducted to evaluate the safety, pharmacokinetic behavior and immunogenicity of the two preparations in healthy adult female subjects in China, so as to provide a reference for the product marketing.

Start Date13 Mar 2024

Sponsor / Collaborator

Chengdu Zeyan Biotechnology Co., Ltd.

CTR20232741 / RecruitingPhase 3

一项随机、双盲、平行、阳性对照，比对 JZB05 和阿柏西普在糖尿病黄斑水肿患者中的有效性及安全性特征的多中心Ⅲ期临床试验

[Translation] A randomized, double-blind, parallel, positive-controlled, multicenter phase III clinical trial comparing the efficacy and safety of JZB05 and aflibercept in patients with diabetic macular edema

主要目的：比较在DME患者中玻璃体腔注射JZB05注射液和阿柏西普眼内注射溶液（EYLEA®）的临床有效性的相似性。临床有效性的相似性评价基于：给予JZB05和EYLEA®后第8周采用ETDRS视力表测得的最佳矫正视力（BCVA）较基线改善的字母数。

[Translation]

Primary objective: To compare the similarity of clinical effectiveness of intravitreal JZB05 injection and aflibercept intraocular injection solution (EYLEA®) in patients with DME. The similarity of clinical effectiveness was evaluated based on the number of letters of improvement in best corrected visual acuity (BCVA) measured by the ETDRS eye chart compared with baseline at week 8 after administration of JZB05 and EYLEA®.

Start Date09 Oct 2023

Sponsor / Collaborator

Shanghai Jingze Biotechnology Co., Ltd.

[+1]

100 Clinical Results associated with Jiangsu Jingze Biomedical Co Ltd

Login to view more data

0 Patents (Medical) associated with Jiangsu Jingze Biomedical Co Ltd

Login to view more data

2

Literatures (Medical) associated with Jiangsu Jingze Biomedical Co Ltd

01 Apr 2024·International Journal of Biological Macromolecules

Cm-siRPred: Predicting chemically modified siRNA efficiency based on multi-view learning strategy

Article

Author: Ning, Lin ; Lin, Hao ; Zhang, Yang ; Ren, Liping ; Huang, Jian ; Luo, Delun ; Huang, Junyang ; Liu, Tianyuan

The rational modification of siRNA molecules is crucial for ensuring their drug-like properties. Machine learning-based prediction of chemically modified siRNA (cm-siRNA) efficiency can significantly optimize the design process of siRNA chemical modifications, saving time and cost in siRNA drug development. However, existing in-silico methods suffer from limitations such as small datasets, inadequate data representation capabilities, and lack of interpretability. Therefore, in this study, we developed the Cm-siRPred algorithm based on a multi-view learning strategy. The algorithm employs a multi-view strategy to represent the double-strand sequences, chemical modifications, and physicochemical properties of cm-siRNA. It incorporates a cross-attention model to globally correlate different representation vectors and a two-layer CNN module to learn local correlation features. The algorithm demonstrates exceptional performance in cross-validation experiments, independent dataset, and case studies on approved siRNA drugs, and showcasing its robustness and generalization ability. In addition, we developed a user-friendly webserver that enables efficient prediction of cm-siRNA efficiency and assists in the design of siRNA drug chemical modifications. In summary, Cm-siRPred is a practical tool that offers valuable technical support for siRNA chemical modification and drug efficiency research, while effectively assisting in the development of novel small nucleic acid drugs. Cm-siRPred is freely available at https://cellknowledge.com.cn/sirnapredictor/.

01 Dec 2022·International Journal of Oral Science

Advances in regenerative medicine applications of tetrahedral framework nucleic acid-based nanomaterials: an expert consensus recommendation

Review

Author: Wang, Lihua ; Tian, Xudong ; Li, Haihang ; Lin, Yunfeng ; Li, Qian ; Guo, Quanyi ; Luo, Delun ; Shi, Sirong ; Liu, Shuyun ; Sun, Yong ; Zhu, Shihui ; Fan, Yujiang ; Sun, Yu

AbstractWith the emergence of DNA nanotechnology in the 1980s, self-assembled DNA nanostructures have attracted considerable attention worldwide due to their inherent biocompatibility, unsurpassed programmability, and versatile functions. Especially promising nanostructures are tetrahedral framework nucleic acids (tFNAs), first proposed by Turberfield with the use of a one-step annealing approach. Benefiting from their various merits, such as simple synthesis, high reproducibility, structural stability, cellular internalization, tissue permeability, and editable functionality, tFNAs have been widely applied in the biomedical field as three-dimensional DNA nanomaterials. Surprisingly, tFNAs exhibit positive effects on cellular biological behaviors and tissue regeneration, which may be used to treat inflammatory and degenerative diseases. According to their intended application and carrying capacity, tFNAs could carry functional nucleic acids or therapeutic molecules through extended sequences, sticky-end hybridization, intercalation, and encapsulation based on the Watson and Crick principle. Additionally, dynamic tFNAs also have potential applications in controlled and targeted therapies. This review summarized the latest progress in pure/modified/dynamic tFNAs and demonstrated their regenerative medicine applications. These applications include promoting the regeneration of the bone, cartilage, nerve, skin, vasculature, or muscle and treating diseases such as bone defects, neurological disorders, joint-related inflammatory diseases, periodontitis, and immune diseases.

100 Deals associated with Jiangsu Jingze Biomedical Co Ltd

Login to view more data

100 Translational Medicine associated with Jiangsu Jingze Biomedical Co Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

11

2

IND Application

Phase 1 Clinical

2

1

Phase 3 Clinical

NDA/BLA

1

4

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant Human Follicle Stimulating Hormone (Shanghai Jingze ) ( FSHR )	Infertility, Female More	NDA/BLA
Aflibercept biosimilar(Jingze Biotech) ( PGF x VEGF-A )	Diabetic macular oedema More	Phase 3
JZB-32 ( PLG )	Polypoidal choroidal vasculopathy More	Phase 1
Recombinant Human Follitropin Alfa (Jingze Biotechnology) ( FSHR )	Anovulation More	Phase 1
JZB-61	Oligospermia More	Clinical